ATX 3 314 0,3%  Dow 24 585 0,3%  Nasdaq 6 395 0,2%  Euro 1,1842 0,1% 
ATX P 1 674 0,2%  EStoxx50 3 566 -0,5%  Nikkei 22 694 -0,3%  CHF 1,1681 0,2% 
DAX 13 027 -0,8%  FTSE100 7 478 -0,3%  Öl 62,3 -0,8%  Gold 1 257 0,1% 

Neos Therapeutics Aktie [WKN DE: A14XHH / ISIN: US64052L1061]

08.11.2017 13:00:00

Neos Therapeutics Reports Third Quarter 2017 Financial Results


DALLAS and FORT WORTH, Texas, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technologies, today reported financial results for the third quarter ended September 30, 2017, and provided a business update."We recently launched our second ADHD product, Cotempla XR-ODT™, and we are very pleased to report that the prescription trends so far are very encouraging. We believe this is, in part, the result of our established relationships with nearly 10,000 healthcare professionals, their awareness of our XR-ODT technology and their interest in using our innovative products," said Vipin K. Garg, Ph.D., President and CEO of Neos Therapeutics. "Along with our first product, Adzenys XR-ODT®, we expect to see continued commercial growth, and believe that Neos stands out as the only company to have both a branded methylphenidate and a branded amphetamine product available in an extended-release orally disintegrating tablet dosage form. We are also looking forward to the launch of our amphetamine oral suspension product, Adzenys ER™, expected in early 2018."Third Quarter and Recent AnnouncementsOn September 5, 2017, Neos announced a limited-availability early experience program for Cotempla XR-ODT, the first and only methylphenidate extended-release orally disintegrating tablet for the treatment of attention deficit/hyperactivity disorder (ADHD) in patients 6 to 17 years old. The full US commercial launch occurred on October 2, 2017.On September 15, 2017, Adzenys ER (amphetamine) Extended-Release Oral Suspension, a once-daily, extended-release liquid medication that does not require refrigeration or reconstitution at the pharmacy level, received approval from the U.S. Food and Drug Administration (FDA). The Company expects Adzenys ER will be commercially available in early 2018.On October 17, 2017, the Company entered into a confidential settlement and licensing agreement with Actavis Laboratories FL, Inc. (Actavis) to resolve all ongoing litigation involving Neos' patents protecting its Adzenys XR-ODT product. Under the settlement and license agreement, Neos has granted Actavis the right to manufacture and market its generic version of Adzenys XR-ODT under the Actavis Abbreviated New Drug Application beginning on September 1, 2025, or earlier under certain circumstances.In October, the Company presented two posters at the 64th Annual Meeting of the American Academy of Child & Adolescent Psychiatry (AACAP) in Washington, D.C. One showed a lack of food effect, a key favorable attribute of Adzenys ER, and the other presented a PK/PD model for dose optimization of Cotempla XR-ODT tablets in patients with ADHD.Commercial Product Highlights Adzenys XR-ODT®Prescription Trends Continue to Show Strong Growth Momentum: Adzenys XR-ODT continued to perform well, and the cumulative total number of prescriptions filled for Adzenys XR-ODT, as reported by QuintilesIMS, were 50,697 for the three months ended September 30, 2017, an increase of 20.8% over the 41,954 for the three months ended June 30, 2017. Monthly prescriptions through October 27, 2017, for Adzenys XR-ODT, as reported by QuintilesIMS, were 19,036. As of October 27, 2017, the cumulative total number of prescriptions filled for Adzenys XR-ODT since its launch in May 2016, as reported by QuintilesIMS, were 174,323.Number of Prescribers Continues to Increase Nationally: The number of prescribers of Adzenys XR-ODT continued to grow, and as of September 29, 2017, 9,086 health care providers had written prescriptions for the product since its launch. As of the week ended October 13, 2017, that number had increased to 9,542.Doctors are Switching Patients Over to Adzenys XR-ODT: Patients switching from another ADHD medication accounted for approximately 73% of all new Adzenys XR-ODT prescriptions, as reported by QuintilesIMS, as of the week ended October 20, 2017.Product Appeal for All Patient Types: As of the week ended October 20, 2017, as reported by QuintilesIMS, 60% of all new Adzenys XR-ODT prescriptions were for pediatric patients and 40% were for adult patients, indicating a broad appeal of Adzenys XR-ODT in all patient types. Cotempla XR-ODT™  Launch Off to Solid Start: The number of equivalent unit prescriptions filled for Cotempla XR-ODT through September 30, 2017, as reported by QuintilesIMS, during the limited-availability early experience program was 648. Monthly equivalent unit prescriptions through October 27, 2017, for Cotempla XR-ODT, as reported by QuintilesIMS, were 2,100. As of October 27, 2017, the cumulative total number of equivalent unit prescriptions filled for Cotempla XR-ODT since its launch, as reported by QuintilesIMS, were 2,748.Doctors are Switching Patients Over to Cotempla XR-ODT: Patients switching from another ADHD medication accounted for approximately 76% of all new Cotempla XR-ODT prescriptions, as reported by QuintilesIMS, as of the week ended October 20, 2017.Select Financial Results for the Third Quarter Ended September 30, 2017 Total product revenues were $6.7 million for the three months ended September 30, 2017, compared to $1.6 million for the same period in 2016. This includes product revenue associated with dispensed patient prescriptions of Adzenys XR-ODT of $5.3 million and $1.4 million in net sales for generic Tussionex. Sales from the early experience program for Cotempla XR-ODT, which commenced on September 5, 2017, were negligible.The Company reported a gross profit of $4.3 million for the three months ended September 30, 2017, compared to a gross loss of $0.7 million for the same period in 2016.Research and development expenses for the three months ended September 30, 2017, were $1.8 million, compared to $2.9 million for the same period in 2016. The decrease was primarily due to a decline in testing, materials and supply expenses for the Company's ADHD product candidates coupled with a reduction in clinical expenses due to completion of studies for Cotempla XR-ODT and Adzenys ER in 2016.Selling and marketing expenses were $12.6 million for the three months ended September 30, 2017, compared to $17.0 million for the same period in 2016. The decreased expense was due to a decrease in advertising agency fees and other costs expensed in 2016 for the Adzenys XR-ODT launch.General and administrative expenses for the three months ended September 30, 2017, were $3.9 million, compared to $3.1 million for the same period in 2016.The Company reported a net loss of $16.3 million for the three months ended September 30, 2017, compared to a net loss of $25.8 million for the same period in 2016.The Company reported net loss per share of $0.58 for the three months ended September 30, 2017, compared to a net loss per share of $1.61 for the same period in 2016.At September 30, 2017, the Company held $66.5 million in cash and cash equivalents and short-term investments.Conference Call Details ...Full story available on Benzinga.com
Weiter zum vollständigen Artikel bei "Benzinga earnings"

Analysen zu Neos Therapeutics Inc

mehr Analysen
  • Alle
  • Buy
  • Hold
  • Sell
09.08.17 Neos Therapeutics Outperform RBC Capital Markets
01.08.17 Neos Therapeutics Overweight Cantor Fitzgerald
20.03.17 Neos Therapeutics Neutral UBS AG
17.05.16 Neos Therapeutics Outperform RBC Capital Markets

Eintrag hinzufügen

Nachrichten

  • Nachrichten zu Aktien
  • Alle Nachrichten
pagehit